Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.63 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | ADK | P55263 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 7/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28382247 | 0.84 | NISCH (0.62) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL722191 | 0.83 | NISCH (0.78) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL27729601 | 0.81 | NISCH (0.54) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL862114 | 0.81 | NISCH (0.75) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL2903588 | 0.80 | NISCH (0.58) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL674010 | 0.78 | NISCH (1.00) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL8742944 | 0.78 | CYP1A2 (0.43) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL27750051 | 0.77 | NISCH (0.50) | NISCHMTORADKALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL9357414 | 0.77 | CYP1A2 (0.42) | NISCHMTORADKALDH1A1KDM4E | |
| SCHEMBL28230038 | 0.76 | NISCH (0.96) | NISCHMTORADKALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110791547-A | Creatinine quantitative detection dry sheet for in vitro diagnosis | 无锡锦帛诚医疗器械科技有限公司 | 2020-02-14 | — | — | CN | claimed |
| CN-101735217-A | Application of imidazole [4,5-f][1,10] phenanthroline and derivative thereof to preparation of antineoplastic drug | UNIV GUANGDONG PHARM | 2010-06-16 | — | — | CN | claimed |
| CN-101379065-A | Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same | CRYSTALGENOMICS INC (KR) | 2009-03-04 | — | — | CN | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114667097-A | Glycated hemoglobin measurement | 奥索临床诊断有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-110791547-A | Creatinine quantitative detection dry sheet for in vitro diagnosis | 无锡锦帛诚医疗器械科技有限公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| CN-101107521-A | Dry analysis element | FUJIFILM CORP (JP) | 2008-01-16 | — | — | CN | disclosed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0997527-A1 | Stabilisation of peroxidases | Ortho-Clinical Diagnostics (GB) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| US-5756527-A | ANTICARCINOGENIC AGENTS | ONTOGEN CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0577734-A1 | CONTROLLED-RELEASE SOLID PHASE ASSAY DEVICE INCLUDING ENCAPSULATED REAGENTS FOR DETECTING CHEMICAL SUBSTANCES | MICRO RESEARCH, INC. (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1992017769-A1 | CONTROLLED-RELEASE SOLID PHASE ASSAY DEVICE INCLUDING ENCAPSULATED REAGENTS FOR DETECTING CHEMICAL SUBSTANCES | MICRO RESEARCH INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NISCH 3272/4885MTOR 1294/4885ADK 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.